Detalhe da pesquisa
1.
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
Mol Cancer
; 22(1): 200, 2023 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38066564